Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals (Nasdaq: ALNY) will collaborate to identify RNAi therapeutics for non-alcoholic steatohepatitis (NASH) and potentially other related diseases.
The partnership is based on work done by Regeneron around a variant in the HSD17B13 gene, which is associated with a reduced risk of chronic liver diseases.
RNA interference (RNAi) is a natural cellular process of gene silencing, an approach led by Alnylam for a number of years, but one which has yet to yield any approved therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze